Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/de-gruyter/metabolism-resistant-bradykinin-antagonists-development-and-pboFHfSDo6
References (31)
-
J. Stewart, L. Gera, D. Chan, E. Whalley, W. Hanson, J. Zuzack (1997)
Potent, long-acting, orally-active bradykinin antagonists for a wide range of applications.Immunopharmacology, 36 2-3
-
P. Bunn, D. Chan, D. Dienhart, R. Tolley, M. Tagawa, P. Jewett (1992)
Neuropeptide signal transduction in lung cancer: clinical implications of bradykinin sensitivity and overall heterogeneity.Cancer research, 52 1
-
R. Horlick, M. Ohlmeyer, I. Stroke, Barbara Strohl, Gonghua Pan, Adriane Schilling, Paradkar Vidyadhar, Jorge Quintero, Ming You, C. Riviello, Megan Thorn, B. Damaj, V. Fitzpatrick, R. Dolle, M. Webb, J. Baldwin, N. Sigal (1999)
Small molecule antagonists of the bradykinin B1 receptor.Immunopharmacology, 43 2-3
-
F. Marceau, J. Hess, D. Bachvarov (1998)
The B1 receptors for kinins.Pharmacological reviews, 50 3
-
J. Cheronis, E. Whalley, K. Nguyen, S. Eubanks, L. Allen, M. Duggan, S. Loy, K. Bonham, J. Blodgett (1992)
A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers.Journal of medicinal chemistry, 35 9
-
L. Gera, J. Stewart, E. Whalley, M. Burkard, J. Zuzack (1996)
New bradykinin antagonists having very high potency at B1 receptors.Immunopharmacology, 33 1-3
-
M. Jarpe, C. Knall, F. Mitchell, A. Buhl, E. Duzic, G. Johnson (1998)
[d-Arg1,d-Phe5,d-Trp7,9,Leu11]Substance P Acts as a Biased Agonist toward Neuropeptide and Chemokine Receptors*The Journal of Biological Chemistry, 273
-
F. Gobeil, S. Charland, C. Filteau, S. Perron, W. Neugebauer, D. Regoli (1999)
Kinin B1 receptor antagonists containing alpha-methyl-L-phenylalanine: in vitro and in vivo antagonistic activities.Hypertension, 33 3
-
N. Inamura, M. Asano, H. Kayakiri, C. Hatori, T. Oku, K. Nakahara (1997)
Characterization of FR173657, a novel nonpeptide B2 antagonist: in vitro and in vivo studies.Canadian journal of physiology and pharmacology, 75 6
-
F. Hock, K. Wirth, U. Albus, W. Linz, H. Gerhards, G. Wiemer, S. Henke, G. Breipohl, W. König, J. Knolle, B. Schölkens (1991)
Hoe 140 a new potent and long acting bradykinin‐antagonist: in vitro studiesBritish Journal of Pharmacology, 102
-
(1999)
Dimers of bradykinin antagonists and their smaller molecular mimetics as potential anti-cancer drugs -
T. Rodell (1996)
The kallikrein/kinin system and kinin antagonists in trauma.Immunopharmacology, 33 1-3
-
H. Maeda, T. Akaike, J. Wu, Y. Noguchi, Y. Sakata (1996)
Bradykinin and nitric oxide in infectious disease and cancer.Immunopharmacology, 33 1-3
-
D. Chan, L. Gera, B. Helfrich, K. Helm, J. Stewart, E. Whalley, P. Bunn (1996)
Novel bradykinin antagonist dimers for the treatment of human lung cancers.Immunopharmacology, 33 1-3
-
Didier Pruneau, J. Paquet, J. Luccarini, E. Defrêne, Chantal Fouchet, R. Franck, B. Loillier, C. Robert, P. Bélichard, Hervé Duclos, B. Cremers, P. Dodey (1999)
Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist.Immunopharmacology, 43 2-3
-
(1999)
Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin receptor -
J. Jackson, M. Seed, C. Kircher, D. Willoughby, J. Winkler (1997)
The codependence of angiogenesis and chronic inflammationThe FASEB Journal, 11
-
G. Burgess, M. Perkins, H. Rang, E. Campbell, Michael Brown, P. McIntyre, L. Urbán, E. Dziadulewicz, T. Ritchie, A. Hallett, C. Snell, R. Wrigglesworth, Wai Lee, C. Davis, S. Phagoo, Andrew Davis, E. Phillips, Gillian Drake, G. Hughes, Andrew Dunstan, G. Bloomfield (2000)
Bradyzide, a potent non‐peptide B2 bradykinin receptor antagonist with long‐lasting oral activity in animal models of inflammatory hyperalgesiaBritish Journal of Pharmacology, 129
-
J. Salvino, P. Seoane, B. Douty, M. Awad, R. Dolle, W. Houck, D. Faunce, D. Sawutz (1993)
Design of potent non-peptide competitive antagonists of the human bradykinin B2 receptor.Journal of medicinal chemistry, 36 17
-
Jun Wu, Takaaki Akaike, H. Maeda (1998)
Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger.Cancer research, 58 1
-
J. Stewart, L. Gera, W. Hanson, J. Zuzack, M. Burkard, R. McCullough, E. Whalley (1996)
A new generation of bradykinin antagonists.Immunopharmacology, 33 1-3
-
L. Gera, J. Stewart (2002)
Novel highly potent bradykinin antagonists containing pentafluorophenylalanine -
(1985)
Development and modification of competitive antagonists of bradykinin -
P. Bunn, D. Chan, John Stewart, L. Gera, R. Tolley, Philip Jewett, Maureen Tagawa, Charlotte Alford, Tohru Mochzuki, N. Yanaihara (1994)
Effects of neuropeptide analogues on calcium flux and proliferation in lung cancer cell lines.Cancer research, 54 13
-
R. Vavrek, J. Stewart (1985)
Competitive antagonists of bradykininPeptides, 6
-
L. Morbidelli, A. Parenti, L. Giovannelli, H. Granger, F. Ledda, M. Ziche (1998)
B1 receptor involvement in the effect of bradykinin on venular endothelial cell proliferation and potentiation of FGF‐2 effectsBritish Journal of Pharmacology, 124
-
John Stewart, Lajos Gera, E. York, Daniel Chan, Paul Bunn (1999)
Bradykinin antagonists: present progress and future prospects.Immunopharmacology, 43 2-3
-
E. Erdös (1990)
Some Old and Some New Ideas on Kinin MetabolismJournal of Cardiovascular Pharmacology, 15
-
J. Ryan, J. Roblero, J. Stewart (1968)
Inactivation of bradykinin in the pulmonary circulation.Biochemical Journal, 110
-
C. Austin, John Foreman, G. Scadding (1994)
Reduction by Hoe 140, the B2 kinin receptor antagonist, of antigen‐induced nasal blockageBritish Journal of Pharmacology, 111
-
(1998)
Potent, wide-spectrum, orally-active bradykinin antagonists
- Publisher
- de Gruyter
- Copyright
- Copyright © 2001 by the
- ISSN
- 1431-6730
- DOI
- 10.1515/BC.2001.006
- pmid
- 11258669
- Publisher site
- See Article on Publisher Site
Abstract
Abstract Bradykinin plays many roles in normal and pathological physiology, but rapid enzymatic degradation made elucidation of its functions extremely difficult. Development of effective degradation-resistant antagonists made it possible to delineate these roles and to open the way for development of new drugs to control pathology due to excess production of bradykinin. Presently available peptide bradykinin antagonists are extremely potent, are completely resistant to enzymatic degradation, and are orally available. Non-peptide bradykinin antagonists have also been discovered. Development of bradykinin antagonists as drugs for cancer, inflammation and trauma is anticipated.
Journal
Biological Chemistry – de Gruyter
Published: Jan 6, 2001